CLIP Inhibitors Modulate Immune Function via MHC Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate immune function by inhibiting invariant chain expression or ectopic CLIP binding, which are crucial for immune signaling and activation, and have not been explored for therapeutic benefits in diseases such as HIV infection, autoimmune disorders, and cancer.
Innovation Solution
Computational analysis is used to identify peptides that displace CLIP from MHC molecules, allowing for the development of CLIP inhibitors that can modulate immune cell function, promote regulatory T cell activation, and interfere with effector T cell activation, thereby treating various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If invariant chain expression is inhibited or ectopic CLIP binding is blocked, then immune cell function can be modulated and therapeutic benefits achieved, but current methods fail to effectively achieve this inhibition
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to block the interaction between CLIP and MHC class II molecules. These compounds act as mediators that bind to CLIP or MHC class II, preventing their natural interaction and thereby modulating immune function without requiring direct genetic manipulation or complex biological agents.
Solution Approach 2:
The patent employs compounds that alter the binding parameters between CLIP and MHC class II by changing the affinity or occupancy dynamics. By modifying these interaction parameters through small molecule binding, the system achieves effective inhibition of invariant chain function and modulation of immune responses.
2Adaptability or versatility
If CLIP inhibitors are used to promote regulatory T cell activation and interfere with effector T cell activation, then therapeutic benefits for diseases like HIV, autoimmune diseases, and cancer are achieved, but the mechanisms have not been fully explored
Solution Approach 1:
The patent identifies small molecule compounds with universal applicability across multiple disease states including HIV, autoimmune diseases, and cancer. The same CLIP-inhibiting mechanism produces therapeutic benefits in diverse conditions by modulating T cell responses, demonstrating multi-functionality of the inhibition approach.
Solution Approach 2:
The patent utilizes feedback mechanisms where inhibition of CLIP-MHC class II interaction leads to altered T cell activation patterns, which in turn provide information about the effectiveness of inhibition. This feedback loop allows for optimization of therapeutic outcomes and deeper understanding of the molecular mechanisms involved.
Data Source
AI summary
The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.